drugset / Trial / NCT00506779
Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
Objectives: * To determine the maximum tolerated dose (MTD) of imatinib mesylate in combination with fixed dose paclitaxel in patients with stage IIIC, IV or recurrent uterine papillary serous carcinoma. * To determine the nature and degree of toxicity of imatinib mesylate and paclitaxel in this cohort of patients. * To determine the efficacy of imatinib mesylate and paclitaxel in patients with stage IIIC, IV or recurrent uterine papillary serous carcinoma whose tumor expresses either c-Kit, PDGFR or abl.
Timeline
- Start
- 2003-12-29
- Primary completion
- 2015-04
- Completion
- 2015-04
Outcome
Outcome not reported
Stopped (Enrollment): “the study was terminated early due to poor enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 400 mg | Oral |
| Subject | Imatinib | Small molecule | 500 mg | Oral |
| Subject | Imatinib | Small molecule | 600 mg | Oral |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |